Trial Profile
Pemetrexed in Maintenance in Patients With Impaired Renal Function: Randomized Phase 4 Multicenter Study Comparing 2 Dose Calculation Strategies (PKAPIR)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer; Renal failure
- Focus Therapeutic Use
- Acronyms PKAPIR
- 21 May 2021 Status changed from recruiting to completed.
- 23 Jun 2020 Planned End Date changed from 16 Sep 2020 to 6 Jan 2021.
- 07 Aug 2017 New trial record